These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Bigal ME; Walter S; Rapoport AM Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260 [TBL] [Abstract][Full Text] [Related]
31. Treatment of the Patient with Refractory Headache. Zagami AS Curr Pain Headache Rep; 2018 Mar; 22(4):23. PubMed ID: 29556828 [TBL] [Abstract][Full Text] [Related]
32. Neuromodulation of chronic headaches: position statement from the European Headache Federation. Martelletti P; Jensen RH; Antal A; Arcioni R; Brighina F; de Tommaso M; Franzini A; Fontaine D; Heiland M; Jürgens TP; Leone M; Magis D; Paemeleire K; Palmisani S; Paulus W; May A; J Headache Pain; 2013 Oct; 14(1):86. PubMed ID: 24144382 [TBL] [Abstract][Full Text] [Related]
33. Noninvasive neurostimulation methods for migraine therapy: The available evidence. Schoenen J; Roberta B; Magis D; Coppola G Cephalalgia; 2016 Oct; 36(12):1170-1180. PubMed ID: 27026674 [TBL] [Abstract][Full Text] [Related]
34. The role of anti-CGRP antibodies in the pathophysiology of primary headaches. Barbanti P; Aurilia C; Fofi L; Egeo G; Ferroni P Neurol Sci; 2017 May; 38(Suppl 1):31-35. PubMed ID: 28527063 [TBL] [Abstract][Full Text] [Related]
36. Neuromodulation in migraine: state of the art and perspectives. Magis D Expert Rev Med Devices; 2015 May; 12(3):329-39. PubMed ID: 25633885 [TBL] [Abstract][Full Text] [Related]